ClinicalTrials.gg
RecruitingNCT02609685PMCASUpdated Nov 4, 2026

Active Surveillance of Papillary Thyroid Microcarcinoma

An interventional study of Active Surveillance in Papillary Thyroid Microcarcinoma, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2016; still recruiting 10 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.

Read the detailed description

The incidence of thyroid cancer has more than doubled in the last 30 years in the United States, Europe, Canada, and South America. Since nearly 50% of this increase is attributable to papillary thyroid microcarcinomas (PTMC), it appears that greater detection and diagnosis of previously subclinical disease is a major factor driving this dramatic rise.

The primary objective is to estimate the rate of disease progression (growth of primary tumor or development of loco-regional/distant metastases) over a 3, 5, and 10-year period in a series of PTMC patients followed with active surveillance in the United States.

Patients who opt for immediate surgery can participate in a sub-study looking at quality of life and anxiety measures as compared to those patients who enroll in the active surveillance main study. Patients who enroll in active surveillance can choose to have surgery at any time that they and their treating physician feel that it is in their best interest.

02

Conditions studied

  • Papillary Thyroid Microcarcinoma

Keywords

  • Thyroid cancer
  • Active surveillance
  • PTMC
03

In context

Papillary Thyroid Microcarcinoma

24 studies on the registry are indexed under Papillary Thyroid Microcarcinoma; 8 are open to participants now.

Browse Papillary Thyroid Microcarcinoma studies →

Lead sponsor

Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.
  • 2.0 cm or smaller nodules by ultrasonographic criteria
  • Ability to understand and the willingness to sign a written and HIPAA Authorization form
  • Must be able to read and write English fluently to participate in the questionnaire portion of the study

Exclusion criteria

Exclusion Criteria:

  • High-grade or poorly differentiated PTC variants
  • Central or lateral neck lymphadenopathy suspicious for PTC
  • Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)
  • History of radiation to neck
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Other
    Active Surveillance

    Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.

    Other: Active Surveillance

  • No intervention
    Immediate Surgery

    Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered "no intervention" because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma.

Interventions

  • OtherActive Surveillance

    Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.

06

What researchers measure

Primary outcomes

  1. Rate of disease progression

    Time frame: From time of diagnosis up to10 years of follow-up

Secondary outcomes

  1. Percentage of subjects that will elect surgery despite absence of clinical progression

    Time frame: From time of diagnosis up to 10 years of follow-up

  2. Impact of TSH suppression on thyroid nodule growth (in cm) as measured by ultrasound

    Time frame: Five years

  3. Identify the clinicopathologic features associated with disease progression in papillary thyroid microcarcinoma patients followed with active surveillance

    Time frame: Five years

  4. Identify the genetic factors associated with an increased risk of disease progression

    At any time subjects who have enrolled in the active surveillance study can opt to have surgery. Data will be taken from diagnosis to just after surgery.

    Time frame: Five years

  5. Quality of life score as measured by City of Hope Quality of Life Scale

    Time frame: Up to five years

  6. Anxiety score as measured by Memorial Anxiety Scale

    Time frame: Up to five years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, Mallen-St Clair J, Chen MM, Vasquez M, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZS, Braunstein GD, Sacks WL. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2022 Sep 15;8(11):1588-96. doi: 10.1001/jamaoncol.2022.3875. Online ahead of print. PubMed 36107411 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2016 (actual). Primary completion is estimated for Dec 2030, 175 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2015
First posted
Nov 20, 2015
StartActual
May 13, 2016
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02609685
Responsible party
Allen Ho (Director, Head and Neck Cancer Program and Co-Director, Thyroid Cancer Program, Cedars-Sinai Medical Center) — Principal investigator
First posted
Nov 20, 2015
Start date
May 13, 2016
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Allen Ho, MD
Contact
Allen.Ho@cshs.org
310-423-1220
Clinical Trials Navigator
Contact
GroupCancerTrialInformation@cshs.org
Allen Ho, MD
principal investigator · Cedars-Sinal Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion